platinum 789Conclusion. With ∼4 years of follow-up, pembrolizumab plus pemetrexed-platinum continued to provide OS and PFS benefit vs pemetrexed-platinum alone in patients withFinal analysis of the phase III KEYNOTE-789 trial evaluating pemetrexedplatinum chemotherapy with or without pembrolizumab in TKI-resistant, EGFR-mutated, metastatic